MedTrace Logo

Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers

NCT00279734 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2011-04-13

No results posted yet for this study

Summary

Study to assess the ability of healthy subjects to build anitbodies to tetanus and pneumococcal vaccines after receiving a single intravenous dose of Abatacept, a drug which is being developed for the treatment of Rheumatoid Arthritis and which can affect the immune system.

Conditions

Interventions

DRUG

Tetanus + pnemococcal vaccines alone

0 mg + vaccines, Single dose, 28 days.

DRUG

Abatacept + vaccines

Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 70 days.

DRUG

Abatacept + vaccines

Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 56 days.

DRUG

Abatacept + Vaccines

parenteral, IV, 750 mg abatacept + vaccines, Single dose, 84 days.

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2005-01-31
Completion
2005-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00279734 on ClinicalTrials.gov